KLOW vs GLOW stack, is the KPV worth adding for post-op recovery?

Posted by retiredfreya in Protocols & Stacks - 8 points, 4 comments.

So i've been running the wolverine stack on and off for maybe a year now, mostly for tendon stuff and general recovery. Worked well for me so far, my hamstring strain from a few months back cleared up faster than i expected, could be the peptides could just be rest and physio lah.

Now i'm looking at doing a more structured 8-week cycle after a minor procedure and i'm torn between GLOW and KLOW. The only real difference is KPV in the KLOW stack right. GLOW is GHK-Cu plus BPC plus TB, KLOW adds KPV on top of that.

My question is whether the KPV actually adds anything meaningful when you're already running BPC and TB. The mechanism sounds nice on paper, NF-kB inhibition and all that, but does anyone here actually feel a difference between running GLOW vs KLOW? To be fair i've never used KPV on its own so i have no reference point.

Also curious about the dosing schedule. KLOW says BPC and KPV daily, TB and GHK-Cu 2-3x a week. Does anyone split the KPV AM/PM or just one shot? And do you pin everything in the same syringe or separate? Reconstitution math gets a bit messy when you're mixing four compounds in one vial leh.

Anyone who's run both care to chime in?

Comments

• sleep_sean: Basically my question too, I've been looking at KPV and the anti-inflammatory angle sounds good on paper but I can't find much actual human data behind it. Most of the stuff I've seen is rodent or in vitro and you know how that translates, sometimes it just doesn't. The NF-kB pathway is heaps more complex than "inhibit it and you heal faster," so I'm skeptical it adds a ton when BPC is already in the mix. Have you come across any decent citations on KPV in actual human recovery contexts? Becaus
• retiredfreya: Yeah thats exactly my worry, the human data is basically non-existent from what i can find. To be fair most of what comes up is either rodent models or cell culture stuff and like you said NF-kB isn't a simple on-off switch. I haven't found anything solid on KPV in actual post-op or recovery contexts either. Your reply got cut off at "for the", were you about to say something about the dosing schedule? Would love to hear what you were thinking on that part.
• fasted_scientist: Ngl you're spot on, the KPV human data is basically nonexistent. I went looking a while back and all I could find was the melanocortin receptor stuff from animal models and a couple of in vitro papers on intestinal inflammation. Nothing in actual post-op or soft tissue recovery in humans that I've seen. The NF-kB point is a good one too. People talk about it like it's a simple on/off switch but it's tangled up in so many downstream pathways that inhibiting it broadly could do things you don't w
• retiredfreya: Yeah that's kind of what i suspected leh. The NF-kB thing especially, i keep seeing people talk about it like it's this clean anti-inflammatory switch but broad inhibition sounds like it could mess with stuff you actually want happening post-op, like immune signalling for tissue repair right. To be fair the animal data being mostly gut-focused is a red flag for me too, totally different context from soft tissue healing. Did you end up just sticking with GLOW then, or did you try KPV anyway despi

Community discussion - research and educational context only. Not medical advice.